TP53 and neoplasm: Building on our learning from the two prior trials with Ad.p53-DC, the current investigational protocol restricts accrual to those patients with p53 protein tissue expression above 50% and incorporates the measurement of tumor mutation burden, in an attempt to develop predictive biomarkers for this combinatorial immunotherapeutic strategy.